Effects of treatment with metformin and/or sitagliptin on beta‐cell function and insulin resistance in prediabetic women with previous gestational diabetes. Issue 4 (26th December 2019)

• Record Type: Journal Article
• Authors: Daniele, Giuseppe; Tura, Andrea; Dardano, Angela; Bertolotto, Alessandra; Bianchi, Cristina; Giusti, Laura; Kurumthodathu, Jancy Joseph; Del Prato, Stefano
• Is Part Of: Diabetes, obesity & metabolism. Volume 22:Issue 4(2020)
• Page Start: 648
• Page End: 657
• Publication Date: 2019-12-26
• Subjects: gestational diabetes -- impaired glucose regulation -- metformin -- sitagliptin -- type 2 diabetes prevention; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.13940
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract: Aim: To investigate the effect of sitagliptin (SITA) and metformin (MET) monotherapy as well as in combination (MET+SITA) on beta‐cell function and insulin sensitivity in women with recent gestational diabetes (GDM) and impaired glucose regulation (IGR: impaired fasting glucose and/or impaired glucose tolerance). Material and Methods: Forty women were randomly assigned to receive SITA (100 mg qd), MET (850 mg bid) or MET+SITA (50 + 850 mg bid) for 16 weeks. A 75 g oral glucose tolerance test (OGTT) and +125 mg/dL hyperglycaemic clamp followed by 5 g i.v. L‐arginine were performed at baseline and end of study. The primary outcome of the study was the mean change in arginine‐stimulated insulin secretion rate during the hyperglycaemic clamp test from baseline to 16‐week therapy. Results: At week 16, body mass index declined in all groups (−1.2 ± 0.2 kg/m 2 ; P < 0.05). MET+SITA gave a greater increase of first phase(2–10 min) insulin secretion and arginine‐stimulated response (720.3 ± 299.0 to 995.5 ± 370.3 pmol/L and 3.2 ± 0.6 to 4.8 ± 1.0 pmoL/min, respectively, both P < 0.05) compared with MET and SITA. Similarly, MET+SITA was more effective in increasing OGTT‐based glucose sensitivity (55.7 ± 11.3 to 108 ± 56.2 pmol x min −1 m −2 x mM −1 ; P = 0.04) and insulin‐stimulated glucose disposal (M/I: 2.2 ± 0.5 to 4.6 ± 1.3 mg/kg/min÷μIU/min/ml; P = 0.04; Matsuda index [SI]: 3.1 ± 0.4 to 5.7 ± 1.1; P = 0.03) compared with either MET or SITA. Disposition index (ISSI‐2) increased with MET+SITA and SITA (both P < 0.05), while no significant change was observed in MET. Among MET+SITA women, 33% reverted to normal glucose tolerance (NGT) compared with 14% with MET and 7% with SITA ( P < 0.05). Conclusion: This study shows that MET+SITA is superior to SITA and MET monotherapy regarding beta‐cell function and insulin sensitivity improvement in IGR women with previous GDM, and may offer a potential pharmacologic intervention to reduce the risk of type 2 diabetes in this high‐risk population.